4 Undervalued Stocks Worth Investigating: Where I See Opportunity in Fresenius Medical Care, Bristol Myers Squibb, Watsco, and Devon Energy
Four companies, four different investment stories, and one question every value investor should ask: Am I buying a genuinely undervalued business, or am I simply buying something that has gotten cheaper for a very good reason?
October 16, 2026 | Stock Analysis • Value Investing • Dividend Investing
I've always believed that some of the best opportunities in the stock market emerge when investors become frustrated, impatient, or simply lose interest in otherwise respectable businesses. Wall Street has a remarkable ability to convince itself that a company experiencing temporary difficulties must be permanently damaged. Sometimes that pessimism is justified. Other times, it creates precisely the kind of valuation disconnect that patient investors should be looking for.
The challenge is knowing the difference.
As I examine the market in October 2026, I'm increasingly interested in companies that offer something more tangible than an exciting growth narrative. I want operating cash flow, competitive advantages, sensible capital allocation, and valuations that don't require everything to go perfectly for shareholders to earn a reasonable return.
That doesn't mean I'm abandoning growth investing or declaring that technology stocks have become uninvestable. It simply means I'm unwilling to pay any price for a fashionable investment theme when established businesses may offer more attractive combinations of risk and potential reward.
Four companies currently deserve a closer look: Fresenius Medical Care (FMS), Bristol Myers Squibb (BMY), Watsco (WSO), and Devon Energy (DVN).
These businesses have very little in common operationally. One provides essential dialysis treatment. Another develops and commercializes pharmaceuticals. The third distributes heating and cooling equipment. The fourth produces oil and natural gas.
But all four invite the same fundamental question: Is the market underestimating their future cash-generating ability?
I'm not expecting all four investments to work. In fact, I would be suspicious of any analysis that confidently promised such an outcome. Each business has meaningful risks, and some of those risks could explain why the stocks trade below estimated intrinsic value.
What interests me is whether the potential rewards justify accepting those risks.
The valuation snapshot: Four discounts, four different stories
The following table uses October 14, 2026, closing prices and the Morningstar fair-value estimates provided in the initial shortlist. Morningstar's October 12 screen independently confirms the $38 fair value for Fresenius Medical Care and $433 for Watsco. The $70 estimate for Bristol Myers and $62 for Devon remain reference assumptions from the supplied shortlist rather than separately verified current Morningstar estimates.
Company | Ticker | Oct. 14 price | Reference fair value | Discount |
|---|---|---|---|---|
Fresenius Medical Care | FMS | $21.54 | $38.00 | 43.3% |
Bristol Myers Squibb | BMY | $59.28 | $70.00 | 15.3% |
Watsco | WSO | $295.09 | $433.00 | 31.8% |
Devon Energy | DVN | $49.92 | $62.00 | 19.5% |
As of October 14, 2026. A larger discount is not automatically a better investment.
At first glance, Fresenius looks like the obvious bargain. A stock trading more than 40% below an analyst's fair-value estimate certainly gets my attention.
But I've learned that a large discount isn't automatically a margin of safety. Sometimes the price is wrong. Sometimes the estimate is wrong. And sometimes the assumptions underlying the estimate become outdated before investors realize what's happening.
The trick isn't identifying the biggest percentage discount. It's identifying the company where the gap between price and underlying business value is most likely to close without exposing shareholders to unreasonable permanent losses.
That's the standard I'm applying to these four candidates.
1. Fresenius Medical Care (FMS): A healthcare turnaround with substantial upside potential
If I were looking strictly at the gap between the current share price and estimated fair value, Fresenius Medical Care would immediately rise to the top of my research list.
The company operates one of the world's largest dialysis care networks and manufactures products used to treat kidney disease. This is not a business built around consumers purchasing the latest fashionable product. It provides services that patients depend upon for survival.
That makes its underlying demand characteristics particularly interesting.
At the end of June 2026, Fresenius Medical Care was treating approximately 289,610 patients across 3,513 dialysis clinics worldwide. Its geographic reach, clinical infrastructure, and equipment operations give it a substantial position in a highly specialized healthcare market.
I like businesses with recurring demand. I especially appreciate situations where recurring demand is paired with a credible opportunity to improve profitability.
And that's where the Fresenius thesis becomes more interesting.
The operating recovery is becoming visible
In the second quarter of 2026, Fresenius reported organic revenue growth of 5% and a 23% increase in adjusted operating income. Its adjusted operating margin reached 11.7%, while adjusted earnings per share increased 28%. The company also generated €860 million in operating cash flow and €625 million in free cash flow during the quarter.
Those are meaningful improvements.
But I wouldn't rush to extrapolate one quarter's growth indefinitely. Healthcare companies can benefit from reimbursement changes, operating efficiencies, temporary payment arrangements, and other factors that don't necessarily repeat forever.
What I'm looking for is evidence that the company can convert operational improvements into durable cash generation.
Fresenius has been pursuing cost reductions, operational efficiencies, and improvements in its care delivery network. If those initiatives permanently improve margins rather than merely producing temporary financial benefits, shareholders could see better earnings even without extraordinary revenue growth.
That distinction matters.
A company doesn't necessarily need to increase sales 15% annually to create significant shareholder value. Sometimes improving an operating margin by a couple of percentage points on a large revenue base can materially change earnings power.
Why the valuation gets my attention
At $21.54 per share, compared with Morningstar's $38 estimate, the indicated discount is 43.3%.
If that fair-value estimate were ultimately realized, the implied share-price appreciation would be approximately 76.4%.
That's upside to a valuation assumption, not a forecast or a promise.
And Morningstar specifically categorizes uncertainty around Fresenius Medical Care's valuation as high, a detail I consider every bit as important as the attractive discount.
The company's second-quarter net leverage ratio stood at approximately 2.6 times EBITDA, within its target range. That's manageable in the context of its business, but it's not the kind of balance sheet I'd describe as having unlimited flexibility.
What could go wrong?
Reimbursement pressure remains a major consideration. A dialysis provider can have relatively predictable patient demand while still facing uncertainty about how much it will receive for delivering care.
Labor expenses, reimbursement policy, treatment economics, and operating execution can all influence profitability.
There's also the question of how treatment patterns may evolve as new kidney and metabolic therapies advance. I wouldn't automatically assume those developments will dramatically disrupt dialysis demand, but ignoring possible long-term medical changes would be careless.
My biggest concern is that investors may be extrapolating an operational recovery that proves slower or less profitable than anticipated.
My investment thesis: Fresenius is a potentially compelling deep-value recovery candidate, but I would require continued evidence of sustainable operating-margin improvement before treating that substantial valuation discount as genuinely available upside.
I see opportunity here. I also see a business that deserves closer monitoring than its share-price discount alone might suggest.
2. Bristol Myers Squibb (BMY): A dividend-paying pharmaceutical giant facing a defining transition
Bristol Myers Squibb represents a different kind of value opportunity.
Unlike Fresenius, where much of my attention centers on operating efficiency, Bristol Myers is primarily a story about replacing revenue that will eventually disappear as major drug patents expire.
And this is exactly why pharmaceutical investing can be deceptively complicated.
A company can look inexpensive based on current earnings while facing a very different earnings profile five years later.
Bristol Myers has established franchises in oncology, cardiovascular medicine, immunology, and other therapeutic areas. Its portfolio includes major products such as Eliquis and Opdivo, alongside newer medicines expected to support future growth.
But successful drugs don't generate patent-protected economics forever.
Eventually, exclusivity ends, competitors enter, and revenue can decline substantially.
That's the challenge Bristol Myers must navigate.
The numbers are stronger than the market's fears might suggest
In the second quarter of 2026, Bristol Myers reported revenue of approximately $13 billion, an increase of 6% year over year. Its Growth Portfolio generated $7.6 billion in revenue, increasing 15%. Management raised full-year revenue guidance to approximately $49 billion to $50 billion and adjusted earnings guidance to $6.75 to $7.00 per share.
I find that performance encouraging because the company's ability to grow newer therapies is central to the investment case.
Using the reference share price of $59.28 and the company's 2026 adjusted earnings guidance, the stock trades at approximately 8.5 to 8.8 times guided adjusted earnings.
That appears inexpensive.
But I would be making a serious analytical mistake if I stopped there.
Adjusted earnings aren't the same as GAAP earnings or free cash flow, and pharmaceutical companies can incur meaningful acquisition, research, development, and restructuring costs.
More importantly, the earnings multiple doesn't tell me how much profit may be lost when major products face generic or biosimilar competition.
The proper valuation question isn't simply what Bristol Myers earns today.
It's what the company can sustainably earn after its portfolio changes.
The pipeline offers genuine reasons for optimism
Recent clinical developments provide important context.
On October 12, Bristol Myers announced positive late-stage results for its radiopharmaceutical cancer treatment RYZ101. The company also reported that a lower dose of admilparant met the primary endpoint in a Phase 3 trial for idiopathic pulmonary fibrosis, although the higher dose did not.
These results strengthen the case that Bristol Myers has multiple potential future growth drivers.
Still, I wouldn't count projected drug revenue as though it were already sitting in the bank.
Regulatory approval, manufacturing capacity, physician adoption, competitive treatments, and reimbursement all influence whether a successful clinical program becomes a successful commercial product.
Investors should distinguish scientific progress from realized shareholder value.
The dividend adds another dimension
Bristol Myers declared a quarterly dividend of $0.63 per share in September 2026. At an annualized $2.52 per share and the reference price of $59.28, that represents an indicated dividend yield of approximately 4.25%.
That's attractive to me as someone who appreciates receiving income while waiting for an investment thesis to develop.
But I never buy a pharmaceutical company solely for its dividend.
The cash distribution is sustainable only if the company continues generating sufficient cash after funding research, operations, and financial obligations.
The patent cliff is the central risk. A generous dividend cannot compensate investors for a large and permanent decline in underlying business value.
My investment thesis: Bristol Myers offers a potentially attractive balance of current income, reasonable valuation, and pipeline-driven recovery potential. It is one of my preferred candidates for further research, provided new product growth continues to offset pressure on older franchises.
For investors comfortable with pharmaceutical uncertainty, this is a more interesting opportunity than the surface-level earnings multiple alone suggests.
3. Watsco (WSO): A dividend growth company getting caught in an industry slowdown
Watsco may be the most interesting company on this list from a long-term business-quality perspective.
It also happens to operate in an industry that rarely gets people excited at cocktail parties.
Heating, ventilation, and air conditioning distribution.
I know. Try to contain your enthusiasm.
But I've never believed that successful investing requires finding the most exciting businesses. Quite often, I prefer companies selling products that customers need regardless of whether those products make compelling headlines.
Watsco distributes HVAC equipment, parts, and supplies across North America. Its customers include contractors and technicians who install, maintain, and replace heating and cooling systems.
The company's scale, distribution network, customer relationships, and technology investments provide advantages that smaller competitors may struggle to replicate.
And while demand can fluctuate with housing activity and economic conditions, heating and cooling equipment eventually needs repair or replacement.
A broken air conditioner in the middle of an Atlanta summer doesn't particularly care what the Federal Reserve is doing.
Why I'm interested in the recent weakness
Morningstar's October 12 report identified Watsco as newly entering its five-star category after a substantial share-price decline. Its fair-value estimate stood at $433, and Morningstar assigned the company a narrow economic moat and medium uncertainty rating.
Using the supplied October 14 price of $295.09, shares trade approximately 31.8% below that fair-value estimate.
For a company with an established distribution platform and a history of returning cash to shareholders, that's enough of a discount to make me investigate.
But the recent weakness isn't occurring without reason.
The HVAC industry has experienced uneven demand, and Watsco must navigate changes in replacement cycles, equipment costs, contractor inventories, and consumer spending.
The second quarter of 2026 offered some encouraging signs. Watsco reported approximately 1% same-store sales growth, and management described further signs of industry stabilization. The company also acquired Jackson Supply, a distributor with approximately $230 million in annualized sales across 25 locations.
What I find attractive is the opportunity for Watsco to benefit from an eventual recovery in replacement demand while expanding through acquisitions.
However, I wouldn't automatically assume that weak demand today guarantees unusually strong demand tomorrow.
Consumers can postpone major purchases longer than investors expect. Contractors can reduce inventories. Housing markets can remain sluggish for extended periods.
The question is whether the current share price already reflects a sufficiently pessimistic outlook.
Dividend growth is a major attraction
Watsco increased its quarterly dividend to $3.30 per share in April 2026, representing an annualized payout of $13.20. The company maintained that rate in its October dividend declaration.
At $295.09 per share, that annualized payment represents an indicated dividend yield of approximately 4.47%.
For a company with Watsco's long history of dividend payments, I find that appealing.
But I want to emphasize something that income investors sometimes overlook: dividend history is not the same thing as dividend safety.
Watsco has maintained a conservative balance sheet, and its financial flexibility has historically supported shareholder distributions. Nevertheless, the sustainability of its dividend ultimately depends on future cash generation.
A strong dividend should be evaluated against earnings, operating cash flow, capital expenditures, acquisitions, and working-capital requirements.
I particularly want to examine how inventory movements influence free cash flow throughout the HVAC cycle.
Distributors can report respectable accounting profits while temporarily consuming cash to maintain inventory.
That isn't necessarily a problem, but it matters when evaluating the reliability of shareholder distributions.
What would make Watsco attractive to me?
I would look for three developments: continued stabilization in same-store sales, evidence that operating margins are holding up despite industry pressure, and disciplined capital allocation.
I would also pay attention to whether the company's technology investments strengthen customer retention and distribution efficiency.
Watsco has spent years developing digital tools for contractors. If those systems increase customer loyalty and improve operating productivity, they could provide meaningful competitive advantages over time.
Still, there's a difference between possessing excellent technology and translating that technology into higher returns on invested capital.
I want the financial evidence.
My investment thesis: Watsco is my preferred long-term business-quality candidate of the four, particularly for investors who appreciate dividend growth. The recent valuation compression makes it more appealing, although I would want additional confirmation that industry conditions are stabilizing before becoming aggressive.
Sometimes the most interesting opportunities are hiding inside businesses that nobody feels compelled to discuss at dinner.
Watsco fits that description beautifully.
4. Devon Energy (DVN): An attractive energy valuation with a commodity-price problem
Devon Energy is probably the easiest company on this list to misunderstand.
When oil prices are high, energy companies can produce extraordinary cash flows. Investors see substantial earnings, dividends, and share repurchases, and suddenly the entire industry looks like a bargain.
Then oil prices decline, cash flow contracts, and yesterday's inexpensive stock starts looking considerably more expensive.
That's why I approach energy valuations differently from those of many other businesses.
With Devon, I don't want to know only how much cash the company generated during its strongest quarter.
I want to know how much cash it can generate under less favorable commodity conditions.
The business has changed significantly
Devon completed its merger with Coterra Energy on May 7, 2026, creating a larger oil and gas producer with a diversified asset portfolio.
In the second quarter, the combined company reported approximately 503,000 barrels of daily oil production, $3.7 billion in GAAP operating cash flow, and $1.7 billion in adjusted free cash flow after excluding certain restructuring impacts.
Those figures are substantial.
The enlarged company's asset base and scale provide opportunities to improve drilling efficiency, reduce overhead, and allocate capital toward its most productive properties.
Management also indicated that it was targeting approximately $1 billion in annual pre-tax merger synergies by the end of 2027.
That could become a meaningful driver of shareholder value.
But I want to be careful about giving companies credit for financial benefits they haven't yet delivered.
Merger synergies look fantastic in investor presentations.
Actually realizing those savings while integrating operations, systems, employees, and capital budgets is another matter.
Valuation and commodity exposure
At the reference share price of $49.92, Devon trades approximately 19.5% below the supplied $62 fair-value assumption.
If that valuation were realized, the implied price appreciation would be approximately 24.2%.
That's meaningful, but the discount is smaller than the comparable figures for Fresenius or Watsco.
More importantly, Devon's intrinsic value is highly sensitive to commodity-price assumptions.
A valuation using sustained strong oil prices may look completely different from one assuming several years of subdued prices.
Natural gas prices, production decline rates, capital expenditure requirements, and service costs also influence the company's economic outlook.
This is where investors need to be particularly disciplined.
I wouldn't calculate Devon's value using peak-cycle cash flows and then pretend I've discovered an unusually cheap stock.
I'd rather use conservative commodity assumptions and be pleasantly surprised.
Shareholder returns look attractive, but I want discipline
Following its merger, Devon increased its quarterly fixed dividend to $0.32 per share, equivalent to an annualized $1.28.
At the reference price of $49.92, that translates to an indicated yield of approximately 2.56%.
The company also announced an $8 billion share repurchase authorization. As of the second-quarter report, Devon had approximately $11.4 billion of outstanding debt and $1 billion in cash.
Repurchases could create value if management buys shares below intrinsic value.
But repurchases can also destroy value when companies become overly enthusiastic during favorable commodity cycles.
I've never understood why investors automatically celebrate every share repurchase announcement.
A company buying overpriced shares is no more intelligent than an individual investor doing the same thing.
The relevant questions are whether the shares are genuinely undervalued and whether using cash for repurchases is better than reducing debt or investing in productive assets.
My investment thesis: Devon offers attractive potential for investors comfortable with commodity exposure and merger integration risk. However, I consider it the most cyclical candidate in this group, and I wouldn't make the investment without stress-testing free cash flow against weaker energy prices.
How the four candidates compare for dividend investors
Dividend income is one reason these businesses deserve attention, although their distributions carry different risks.
Company | Annualized dividend | Indicated yield* |
|---|---|---|
Watsco (WSO) | $13.20 | 4.47% |
Bristol Myers (BMY) | $2.52 | 4.25% |
Devon Energy (DVN) | $1.28 | 2.56% |
Fresenius (FMS) | Not compared | — |
What strikes me is that Watsco and Bristol Myers offer similar indicated yields despite having entirely different business risks.
Watsco's dividend depends on industrial distribution economics, housing-related demand, operating margins, and cash conversion.
Bristol Myers' dividend depends heavily on its ability to replace revenue from aging drug franchises.
Devon's dividend is exposed more directly to commodity-price cycles.
I wouldn't choose among them based solely on the highest yield. I'd focus on where the dividend appears most sustainable relative to normalized cash generation.
My ranking: Which stock would I research first?
After evaluating the business models, valuations, financial results, and identifiable risks, here's how I would prioritize further research.
1
Watsco (WSO) — Best long-term business-quality candidate
My preference for investors seeking an established distribution business, dividend growth, and potential recovery from a cyclical slowdown. The key risk is that HVAC demand takes longer to rebound than expected.
2
Bristol Myers Squibb (BMY) — Best income-and-valuation combination
An attractive indicated yield and seemingly modest earnings multiple, offset by substantial patent-expiration risk. Pipeline execution will determine whether today's valuation becomes a genuine bargain.
3
Fresenius Medical Care (FMS) — Biggest potential revaluation opportunity
The widest estimated valuation discount, supported by improving profitability. High valuation uncertainty, reimbursement sensitivity, and execution risk prevent me from ranking it higher.
4
Devon Energy (DVN) — Best for investors comfortable with commodity cycles
Significant assets, cash generation, and merger-related opportunities, but considerable exposure to unpredictable energy prices and integration outcomes.
This isn't a prediction of which stock will perform best over the next twelve months.
It's my ranking of the opportunities based on business characteristics, risk, and the quality of the investment thesis.
The stock with the greatest upside potential isn't necessarily the stock I most want to own.
That's one of the most important lessons I've learned about investing.
What could change my opinion?
I'm not interested in becoming emotionally attached to an investment thesis.
I want the facts to determine whether I continue believing in a company.
For Watsco, I would reconsider my enthusiasm if operating margins deteriorate substantially, same-store sales continue weakening, or inventory management places sustained pressure on cash flow.
For Bristol Myers, persistent declines in established drug revenue without sufficient replacement growth would undermine the thesis. Clinical disappointments or unfavorable regulatory developments could also change the investment case.
For Fresenius, I'd watch reimbursement developments, operating-margin sustainability, cash generation, and leverage. A turnaround dependent on temporary benefits rather than structural improvements would deserve a lower valuation.
For Devon, weaker commodity prices, disappointing merger integration, rising debt, or poor capital allocation would significantly reduce my confidence.
The point is to establish what success and failure look like before buying.
Otherwise, it's far too easy to turn every disappointing development into another excuse to hold a losing investment.
Final thoughts: Cheap stocks are easy to find. Good investments require more work.
I've never believed that successful value investing is simply a matter of buying stocks trading below analyst price targets.
If it were that easy, everyone with a brokerage account and an internet connection would become wealthy.
The difficult part is understanding why a stock is inexpensive, whether the underlying business is worth owning, and how much uncertainty I'm willing to accept.
Fresenius Medical Care offers a potentially substantial recovery opportunity, but its valuation discount reflects real operating and healthcare-system risks.
Bristol Myers Squibb combines attractive current income with an important pharmaceutical transition, making future pipeline success essential.
Watsco has the kind of established operating model and shareholder-return history I appreciate, but its cyclical environment demands patience.
Devon Energy offers meaningful cash-generation potential, although investors must be prepared for the volatility inherent in commodity businesses.
Of the four, Watsco would be my first choice for deeper long-term research, followed closely by Bristol Myers for its income potential. Fresenius deserves serious attention from more aggressive value investors, while Devon may be best suited to portfolios deliberately seeking energy exposure.
That doesn't mean I would purchase any of them blindly at the reference prices.
I would revisit current quotations, update valuation assumptions, review upcoming earnings, and consider the role each position would play in a diversified portfolio.
And I would keep reminding myself of something that has saved me from plenty of questionable investments:
A stock isn't a bargain simply because it used to cost more.
A dividend isn't safe simply because management has paid it for years.
And a price target isn't a guarantee simply because it came from a respected research organization.
The real opportunity comes when I can buy a durable business at a price that adequately compensates me for the risks I'm taking.
That's what I'm looking for in these four stocks.
Not excitement. Not hype. Not a perfect story.
Just a reasonable price for a business capable of creating lasting shareholder value.
Research note: Company results and dividend declarations cited above are from available filings and announcements through October 16, 2026. The valuation comparison uses October 14 reference prices, and two of the four fair-value estimates were not independently reconfirmed. This article presents investment research and opinion, not individualized financial advice. All investments involve risk, including potential loss of principal.
Comments
Post a Comment